ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation

Nature Cell Biology

Volumn 10, Issue 2, 2008, Pages 138-148

  Yang, Jer Yen ^a,b   Zong, Cong S ^a   Xia, Weiya ^a   Yamaguchi, Hirohito ^a   Ding, Qingqing ^a   Xie, Xiaoming ^a   Lang, Jing Yu ^a   Lai, Chien Chen ^c   Chang, Chun Ju ^a   Huang, Wei Chien ^a   Huang, Hsin ^d   Kuo, Hsu Ping ^a,b   Lee, Dung Fang ^a,b   Li, Long Yuan ^c,d   Lien, Huang Chun ^e   Cheng, Xiaoyun ^a,b   Chang, King Jen ^e   Hsiao, Chwan Deng ^f   Tsai, Fuu Jen ^c   Tsai, Chang Hai ^c,d   Sahin, Aysegul A ^a   Muller, William J ^g   Mills, Gordon B ^a   Yu, Dihua ^a,b   Hortobagyi, Gabriel N ^a   Hung, Mien Chie ^a,b,c,d   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d Asian University   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^f INSTITUTE OF MOLECULAR BIOLOGY   (Taiwan)

^g MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; MUTANT PROTEIN; PROTEASOME; PROTEIN MDM2; SERINE; TRANSCRIPTION FACTOR FKHRL1; UBIQUITIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION;

AMINO ACID SEQUENCE; ANIMALS; BREAST NEOPLASMS; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DOWN-REGULATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; MASS SPECTROMETRY; MICE; MICE, NUDE; MOLECULAR SEQUENCE DATA; NEOPLASM TRANSPLANTATION; PHOSPHORYLATION; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-MDM2; SERINE; SIGNAL TRANSDUCTION; TRANSPLANTATION, HETEROLOGOUS;

MURINAE;

EID: 38849139580     PISSN: 14657392     EISSN: None     Source Type: Journal    
DOI: 10.1038/ncb1676     Document Type: Article

References (41)

1. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100 57-70 (2000).
2. Vogelstein, B. & Kinzler, K. W. Cancer genes and the pathways they control. Nature Med. 10, 789-799 (2004).
3. Yoon, S. & Seger, R. The extracellular signal-reguloted kinase: Multiple substrates regulate diverse cellular functions. Growth Factors 24, 21-44 (2006).
4. Kolch, W. Coordinating ERK/MAPK signalling through scaffolds and inhibitors. Nature Rev. Mol. Cell Biol. 6, 827-837 (2005).
5. Thompson, N. & Lyons, J. Recent progress in targetingthe Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. Curr. Opin. Pharmacol. 5, 350-356 (2005).
6. Scholl, F. A., Dumesic, P. A. & Khavari, P. A. Effects of active MEK1 expression in vivo. Cancer Lett. 230, 1-5 (2005).
7. Weinberg, R. A. Fas oncogenes and the molecular mechanisms of carcinogenesis. Blood 64, 1143-1145 (1984).
8. Giehl, K. Oncogenic Ras in tumour progression and metastasis. Biol. Chem. 386, 193-205 (2005).
9. Asada, S. et al. Mitogen-activated protein kinases, Erk and p38, phosphorylate and regulate Foxo1. Cell Signal. 19, 519-527 (2007).
10. Greer, E. L. & Brunet, A. FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 24, 7410-7425 (2005).
11. Finnberg, N. & El-Deiry, W. S. Activating FOXO3a, NF-kappaB and p53 by targeting IKKs: An effective multi-faceted targeting of the tumor-cell phenotype? Cancer Biol. Ther. 3, 614-616 (2004).
12. Burgering, B. M. & Kops, G. J. Cell cycle and death control: Long live Forkheads. Trends Biochem. Sci. 27, 352-360 (2002).
13. Tran, H., Brunet, A., Griffith, E. C. & Greenberg, M. E. The many forks in FOXO's road. Sci STKE RE5 (2003).
14. Dijkers, P. F. et al. Forkhead transcription factor FKHR-L1 modulates cytokine-dependent transcriptional regulation of p27(KIP1). Mol. Cell Biol. 20, 9138-9148 (2000).
15. Schmidt, M. et al. Cell cycle inhibition by FcxO forkhead transcription factors involves downregulation of cyclin D. Mol. Cell Biol. 22, 7842-7852 (2002).
16. Yang, J. Y., Xia, W. & Hu, M. C. Ionizing radiation activates expression of FOXO3a, Fas ligand, and Bim, and induces cell apoptosis. Int. J. Oncol. 29, 643-648 (2006).
17. Hu, M. C. et al. IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell 117, 225-237 (2004).
18. Hu, M. C. & Hung, M. C. Role of IkappaB kinase in tumorigenesis. Future Oncol. 1, 67-78 (2005).
19. Potente, M. et al. Involvement of Foxo transcription factors in angiogenesis and post-natal neovascularization. J. Clin. Invest. 115, 238fs2-2392 (2005).
20. Paik, J. H. et al. FoxOs are fineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell 128 309-323 (2007).
21. Plas, D. R. & Thompson, C. B. Akt activation promotes degradation of tuberin and FOXO3a via the proteasome. J. Biol. Chem. 278, 12361-12366 (2003).
22. Bond, G. L., Hu, W. & Levine, A. J. MDM2 is a central node in the p53 pathway: 12 years and counting. Curr. Cancer Drug Targets 5, 3-8 (2005).
23. Zhou, B. P. et al. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nature Cell Biol. 3, 973-982 (2001).
24. Uchida, C. et al. Enhanced Mdm2 activity inhibits pRB function via ubiquitin-dependent degradation. EMBO J. 24, 160-169 (2005).
25. Yang, J. Y. et al. MDM2 promotes cell motility and invasiveness by regulating E-cadherin degradation. Mol. Cell Biol. 26, 7269-7282 (2006).
26. Ries, S. et al. Opposing effects of Ras on p53: Transcriptional activation of mdm2 and induction of p19ARF. Cell 103, 321-330 (2000).
27. Phelps, M., Phillips, A., Darley, M. & Blaydes, J. P. MEK-ERK signaling controls Hdm2 oncoprotein expression by regulating hdm2 mRNA export to the cytoplasm. J. Biol. Chem. 280, 16651-16658 (2005).
28. Shaw, R. J. & Cantley, L. C. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441, 424-430 (2006).
29. Ding, Q. et al. Erk associates with and primes GSK-3β for its inactivation resulting in-upregulation of β-catenin. Mol. Cell 19, 159-170 (2005).
30. Brunet, A. et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 196, 857-868 (1999).
31. Honda, R. & Yasuda, H. Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligase. Oncogene 19, 1473-1476 (2000).
32. Honda, R. & Yasuda, H. Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBO J. 18, 22-7 (1999).
33. Honda, R., Tanaka, H. & Yasuda, H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420, 25-27 (1997).
34. Medema, R. H., Kops, G. J., Bos, J. L. & Burgering, B. M. AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature 404, 782-787 (2000).
35. Lin, S. Y. et al. β-catenin, a novel prognostic marker for breast cancer: Its roles in cyclin D1 expression and cancer progression. Proc. Natl Acad. Sci. USA 97, 4262-4266 (2000).
36. Tetsu, O. & McCormick, F. β-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398, 422-426 (1999).
37. Storz, R, Doppler, H. & Toker, A. Protein kinase D mediates mitochondrion-to-nucleus signaling and detoxification from mitochondrial reactive oxygen species. Mol. Cell Biol. 25, 8520-8530 (2005).
38. Terry, D. E., Umstot, E. & Desiderio, D. M. Optimized sample-processing time and peptide recovery for the mass spectrometric analysis of protein digests. J. Am. Soc. Mass Spectrom. 15, 784-794 (2004).
39. Lee, D. F. et al. IKKβ suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell 130, 440-455 (2007).
40. Hirosawa, M., Hoshida, M., Ishikawa, M. & Tole, T. MASCOT: Multiple alignment system for protein sequences based on three-way dynamic programming. Comput. Appl. Biosci. 9, 161-167 (1993).
41. Chang, J. Y. et al. The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer. Oncogene 14, 561-568 (1997).